BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Düll MM, Kremer AE. Management of Chronic Hepatic Itch. Dermatologic Clinics 2018;36:293-300. [DOI: 10.1016/j.det.2018.02.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Nietsche TR, Dotta G, Barcaui CB, Ferraz MLCG. Cholestatic pruritus: a knowledge update. Anais Brasileiros de Dermatologia 2022. [DOI: 10.1016/j.abd.2021.06.007] [Reference Citation Analysis]
2 Fourzali KM, Yosipovitch G. Management of Itch in the Elderly: A Review. Dermatol Ther (Heidelb) 2019;9:639-53. [PMID: 31549284 DOI: 10.1007/s13555-019-00326-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
3 Bowlus CL, Galambos MR, Aspinall RJ, Hirschfield GM, Jones DEJ, Dörffel Y, Gordon SC, Harrison SA, Kremer AE, Mayo MJ, Thuluvath PJ, Levy C, Swain MG, Neff GW, Sheridan DA, Stanca CM, Berg CP, Goel A, Shiffman ML, Vierling JM, Boudes P, Steinberg A, Choi YJ, McWherter CA. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol 2022:S0168-8278(22)00187-8. [PMID: 35367282 DOI: 10.1016/j.jhep.2022.02.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Metz M. Treatments for chronic pruritus outside of the box. Exp Dermatol 2019;28:1476-81. [DOI: 10.1111/exd.14007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
5 Sanjel B, Shim WS. Recent advances in understanding the molecular mechanisms of cholestatic pruritus: A review. Biochim Biophys Acta Mol Basis Dis 2020;1866:165958. [PMID: 32896605 DOI: 10.1016/j.bbadis.2020.165958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yu H, Wangensteen K, Deng T, Li Y, Luo W. MRGPRX4 in Cholestatic Pruritus. Semin Liver Dis 2021;41:358-67. [PMID: 34161994 DOI: 10.1055/s-0041-1730923] [Reference Citation Analysis]
7 Bhandari A, Mahajan R. Skin Changes in Cirrhosis. Journal of Clinical and Experimental Hepatology 2022;12:1215-24. [DOI: 10.1016/j.jceh.2021.12.013] [Reference Citation Analysis]
8 Hashimoto T, Yosipovitch G. Itching as a systemic disease. Journal of Allergy and Clinical Immunology 2019;144:375-80. [DOI: 10.1016/j.jaci.2019.04.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
9 Düll MM, Kremer AE. Treatment of Pruritus Secondary to Liver Disease. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0713-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
10 Jain NP, Shao K, Stewart C, Grant-Kels JM. The effects of alcohol and illicit drug use on the skin. Clin Dermatol 2021;39:772-83. [PMID: 34785005 DOI: 10.1016/j.clindermatol.2021.05.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Qu N, Wang X, Meng Y, Shan F. Prospective oncotarget for gynecological cancer: Opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis. Int Immunopharmacol 2019;75:105723. [PMID: 31408839 DOI: 10.1016/j.intimp.2019.105723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Düll MM, Kremer AE. Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease. Curr Hepatology Rep 2020;19:86-95. [DOI: 10.1007/s11901-020-00517-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Yu H, Zhao T, Liu S, Wu Q, Johnson O, Wu Z, Zhuang Z, Shi Y, Peng L, He R, Yang Y, Sun J, Wang X, Xu H, Zeng Z, Zou P, Lei X, Luo W, Li Y. MRGPRX4 is a bile acid receptor for human cholestatic itch. Elife 2019;8:e48431. [PMID: 31500698 DOI: 10.7554/eLife.48431] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
14 Jefremow A, Neurath MF. New agents for immunosuppression. Best Pract Res Clin Gastroenterol 2021;54-55:101763. [PMID: 34874846 DOI: 10.1016/j.bpg.2021.101763] [Reference Citation Analysis]
15 Gurnani P, Miloh T, Chandar J, Landau DA, Hajjar F, Yosipovitch G. Systemic causes of non-dermatologic chronic pruritus in the pediatric population and their management: An unexplored area. Pediatr Dermatol 2021;38:1051-60. [PMID: 34515372 DOI: 10.1111/pde.14596] [Reference Citation Analysis]
16 Sikora M, Rakowska A, Olszewska M, Rudnicka L. The Use of Naltrexone in Dermatology. Current Evidence and Future Directions. Curr Drug Targets 2019;20:1058-67. [PMID: 30887922 DOI: 10.2174/1389450120666190318121122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Esmaeili A, Namazi S. Is melatonin effective for pruritus caused by liver disease? Med Hypotheses 2018;121:177-9. [PMID: 30396475 DOI: 10.1016/j.mehy.2018.10.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Fourzali K, Golpanian RS, Yosipovitch G. Emerging drugs for the treatment of chronic pruritic diseases. Expert Opin Emerg Drugs 2020;25:273-84. [PMID: 32715798 DOI: 10.1080/14728214.2020.1801632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]